Navigation Links
Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics
Date:5/8/2008

BERKELEY, Calif., May 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, is pleased to announce the appointment of Jane Moffitt, J.D., LL.M. as its Vice President of Regulatory Affairs.

"We believe Jane's specific leadership contribution to the launch and development of natriuretic peptide BNP, Natrecor(R), plus her extensive regulatory affairs background will be of great value to Nile as we develop our own natriuretic peptide, CD-NP and cardiovascular pipeline," said Peter Strumph, Chief Executive Officer of Nile.

Ms. Moffitt has over 30 years of professional experience in regulatory affairs and corporate and food & drug law for pharmaceutical, device and biotechnology companies. This experience includes developing clinical regulatory strategies and leading teams responsible for preparing and maintaining INDs, NDAs, BLAs and global product launches. Her drug product expertise includes natriuretic peptides, small molecules and biologics.

Prior to joining Nile, Ms. Moffitt was the West Coast Director of Operations for SciLucent, a specialty healthcare-focused consulting firm. Prior to that, Jane was a Senior Vice President of Quality and Regulatory Affairs at a number of pharmaceutical and medical device companies, including Revance Therapeutics Inc., Scios, Inc., Collagen Corporation, and Amsco International Inc., and worked as a corporate attorney at Miles Laboratories, Inc. At Scios, Ms. Moffitt was a member of the Corporate Management Committee, started the Government Affairs function and was the head of the regulatory affairs function. Ms. Moffitt also served as President, Treasurer and a member of the Board of Directors of Scios R&D, Inc. and BRP, Inc.

Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson College, a J.D. from Dickinson School of Law and a LL.M. in Trade Regulation from New York University School of Law.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric natriuretic peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isilon Named Best of Show at Bio-IT World 2008
2. Flashpoint Medica Named Agency of Year by Medical Advertising News
3. Highmark Inc. Named an Age-Friendly Employer by RetirementJobs.com
4. Boston Scientific Named Healthcare Supplier of the Year by Global Healthcare Exchange (GHX)
5. Trenita Ward Named Vice President, California Member Service Call Centers for Kaiser Permanente
6. WeissComm Partners Named Healthcare Agency of the Year
7. Mental Health Prescription Program Named Winner in URACs Best Practices in Consumer Empowerment and Protection Awards
8. Doug Burcin and Donna Murphy Named Advertising Persons of the Year
9. Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador
10. Laura Loughridge Wargo Named Chief Development Officer for American Red Cross - Southeastern Michigan Chapter
11. Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: